Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

Authors: Choi, Ryan, Hulverson, Matthew A., Huang, Wenlin, Vidadala, Rama S.R., Whitman, Grant R., Barrett, Lynn K., Schaefer, Deborah A., Betzer, Dana P., Riggs, Michael W., Doggett, J. Stone, Hemphill, Andrew, Ortega-Mora, Luis Miguel, McCloskey, Molly C., Arnold, Samuel L.M., Hackman, Robert C., Marsh, Kennan C., Lynch, James J., Freiberg, Gail M., Leroy, Bruce E., Kempf, Dale J., Choy, Robert K.M., de Hostos, Eugenio L., Maly, Dustin J., Fan, Erkang, Ojo, Kayode K., Van Voorhis, Wesley C.

Source: In International Journal for Parasitology May 2020 50(5):413-422

Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis

Authors: Hulverson, Matthew A., Choi, Ryan, Arnold, Samuel L.M., Schaefer, Deborah A., Hemphill, Andrew, McCloskey, Molly C., Betzer, Dana P., Müller, Joachim, Vidadala, Rama S.R., Whitman, Grant R., Rivas, Kasey L., Barrett, Lynn K., Hackman, Robert C., Love, Melissa S., McNamara, Case W., Shaughnessy, Thomas K., Kondratiuk, Alison, Kurnick, Matthew, Banfor, Patricia N., Lynch, James J., Freiberg, Gail M., Kempf, Dale J., Maly, Dustin J., Riggs, Michael W., Ojo, Kayode K., Van Voorhis, Wesley C.

Source: In International Journal for Parasitology October 2017 47(12):753-763

A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation

Authors: Ojo, Kayode K., Eastman, Richard T., Vidadala, RamaSubbaRao, Zhang, Zhongsheng, Rivas, Kasey L., Choi, Ryan, Lutz, Justin D., Reid, Molly C., Fox, Anna M. W., Hulverson, Matthew A., Kennedy, Mark, Isoherranen, Nina, Kim, Laura M., Comess, Kenneth M., Kempf, Dale J., Verlinde, Christophe L. M. J., Su, Xin-zhuan, Kappe, Stefan H. I., Maly, Dustin J., Fan, Erkang, Van Voorhis, Wesley C.

Source: The Journal of Infectious Diseases, 2014 Jan . 209(2), 275-284.

Access URL: http://www.jstor.org/stable/43707958

A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity.

Authors: Alami, Negar, Carter, David C., Kwatra, Nisha V., Zhao, Weihan, Snodgrass, Linda, Porcalla, Ariel R., Klein, Cheri E., Cohen, Daniel E., Gallenberg, Loretta, Neenan, Melina, Carr, Robert A., Marsh, Kennan C., Kempf, Dale J.

Source: PLoS Neglected Tropical Diseases; 7/10/2023, Vol. 17 Issue 7, p1-18, 18p

Subject Terms: PARASITIC diseases, PHARMACOKINETICS, ONCHOCERCIASIS, ADVERSE health care events, FILARIASIS

Geographic Terms: AFRICA

Low-Level Viremia Persists for at Least 7 Years in Patients on Suppressive Antiretroviral Therapy

Authors: Palmer, Sarah, Maldarelli, Frank, Wiegand, Ann, Bernstein, Barry, Hanna, George J., Brun, Scott C., Kempf, Dale J., Mellors, John W., Coffin, John M., King, Martin S.

Source: Proceedings of the National Academy of Sciences of the United States of America, 2008 Mar 01. 105(10), 3879-3884.

Access URL: https://www.jstor.org/stable/25461335

Relationship between Adherence and the Development of Resistance in Antiretroviral-Naive, HIV-1-Infected Patients Receiving Lopinavir/Ritonavir or Nelfinavir

Authors: King, Martin S., Brun, Scott C., Kempf, Dale J.

Source: The Journal of Infectious Diseases, 2005 Jun . 191(12), 2046-2052.

Access URL: https://www.jstor.org/stable/30077867

Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

Authors: Kempf, Dale J., King, Martin S., Bernstein, Barry, Cernohous, Paul, Bauer, Eric, Moseley, Jennifer, Gu, Kai, Hsu, Ann, Brun, Scott, Sun, Eugene

Source: The Journal of Infectious Diseases, 2004 Jan 01. 189(1), 51-60.

Access URL: https://www.jstor.org/stable/30075781

Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats

Authors: Yang, Yi, Dahly-Vernon, Annette J., Blomme, Eric A.G., Lai-Zhang, Jie, Kempf, Dale J., Marsh, Kennan C., Harrington, Yvette A., Nye, Steven H., Evans, Darin L., Roman, Richard J., Jacob, Howard J., Waring, Jeffrey F.

Source: In The Veterinary Journal 2010 185(1):75-82

Design, Activity, and 2.8 Å Crystal Structure of a C$_2$ Symmetric Inhibitor Complexed to HIV-1 Protease

Authors: Erickson, John, Neidhart, David J., VanDrie, John, Kempf, Dale J., Wang, Xiu Chun, Norbeck, Daniel W., Plattner, Jacob J., Rittenhouse, Judith W., Turon, Mary, Wideburg, Norman, Kohlbrenner, William E., Simmer, Robert, Helfrich, Rosalind, Paul, Deborah A., Knigge, Mark

Source: Science, 1990 Aug 01. 249(4968), 527-533.

Access URL: https://www.jstor.org/stable/2874495

ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans

Authors: Kempf, Dale J., Marsh, Kennan C., Denissen, Jon F., McDonald, Edith, Vasavanonda, Sudthida, Flentge, Charles A., Green, Brian E., Fino, Lynnmarie, Park, Chang H., Kong, Xiang-Peng, Wideburg, Norman E., Saldivar, Ayda, Ruiz, Lisa, Kati, Warren M., Sham, Hing L., Robins, Terry, Stewart, Kent D., Hsu, Ann, Plattner, Jacob J., Leonard, John M., Norbeck, Daniel W.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1995 Mar . 92(7), 2484-2488.

Access URL: https://www.jstor.org/stable/2367144

Selection of Multiple Human Immunodeficiency Virus Type 1 Variants that Encode Viral Proteases with Decreased Sensitivity to an Inhibitor of the Viral Protease

Authors: Kaplan, Andrew H., Michael, Scott F., Wehbie, Robert S., Knigge, Mark F., Paul, Deborah A., Everitt, Lorraine, Kempf, Dale J., Norbeck, Daniel W., Erickson, John W., Swanstrom, Ronald

Source: Proceedings of the National Academy of Sciences of the United States of America, 1994 Jun 01. 91(12), 5597-5601.

Access URL: https://www.jstor.org/stable/2364787

A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor

Authors: Healan-Greenberg, Christine, Waring, Jeffrey F. ^*, Kempf, Dale J., Blomme, Eric A.G., Tirona, Rommel G., Kim, Richard B.

Source: In Drug Metabolism and Disposition March 2008 36(3):500-507

HIV protease inhibiting compounds

Macrocyclic hepatitis C serine protease inhibitors

Compounds that are useful for improving pharmacokinetics

Anti-viral compounds

CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF

MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

Anti-viral compounds

NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS